Oscar Alvizo, Fremont, CA (US); David Elgart, San Mateo, CA (US); Robert Kevin Orr, Cranford, NJ (US); James Nicholas Riggins, San Francisco, CA (US); Anna Fryszkowska, New York, NY (US); Katrina W. Lexa, Santa Rosa, CA (US); Xiang Yi, San Carlos, CA (US); Da Duan, Foster City, CA (US); Courtney Dianne Moffett, San Francisco, CA (US); Nikki Dellas, San Carlos, CA (US); and Vesna Mitchell, Santa Clara, CA (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Jan. 23, 2023, as Appl. No. 18/158,339.
Application 16/927,129 is a division of application No. 15/861,849, filed on Jan. 4, 2018, granted, now 10,745,681, issued on Aug. 18, 2020.
Application 18/158,339 is a continuation of application No. 17/091,479, filed on Nov. 6, 2020, granted, now 11,591,588.
Application 17/091,479 is a continuation of application No. 16/927,129, filed on Jul. 13, 2020, granted, now 10,865,402, issued on Dec. 15, 2020.
Claims priority of provisional application 62/472,055, filed on Mar. 16, 2017.
Claims priority of provisional application 62/442,810, filed on Jan. 5, 2017.
Prior Publication US 2023/0227805 A1, Jul. 20, 2023
1. An engineered polynucleotide sequence encoding an engineered penicillin G acylase capable of acylating insulin, wherein the polypeptide sequence of said penicillin G acylase is at least 98%, 99% or more identical to SEQ ID NO:100.